-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although in the past 25 years, new anti-medsci.
medsci.
The study included 18-65-year-old adult patients with focal seizures who were randomized 1:1 (cenopamine: placebo) after an 8-week baseline period.
220 patients were randomized; 113 patients received cenopamine and 109 patients received placebo; 90.
Compared with placebo, the median percentage of seizures in the cenopamine treatment group was reduced (55.
In summary, the results of this study show that adjuvant cenopamine 200 mg/d can significantly improve uncontrolled focal seizures and is well tolerated.
Original source:
Steve S Chung, et al.
ncbi.
nlm.
nih.
gov/32409485/" target="_blank" rel="noopener">Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures in this message